Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00573001 | Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA) | PHASE3 | COMPLETED | 120 | — | — | Jul 1, 2008 | Dec 1, 2011 | May 15, 2012 | 2 | Cameroon, Senegal |
| NCT00561496 | Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel | PHASE1 | COMPLETED | 49 | — | — | Mar 1, 2007 | Apr 1, 2008 | May 28, 2008 | 3 | United States, Dominican Republic |
| NCT00002180 | A Study of PMPA in HIV-Infected Patients | PHASE1 | COMPLETED | - | — | — | - | - | Jun 24, 2005 | 2 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | ACTIVE_COMPARATOR | - |
| Twice daily | OTHER | Tenofovir gel intravaginal twice daily for 14 days |
| Once daily | OTHER | Tenofovir gel intravaginal once daily for 14 days |
| Name | Type | Description |
|---|---|---|
| Tenofovir/Emtricitabine (Truvada) and Nevirapine | DRUG | Tenofovir/Emtricitabine(Truvada) 245/200mg 1cp/day ; Nevirapine 200mg 2cp/day after first 14 days |
| Tenofovir/Emtricitabine/Efavirenz (Atripla) | DRUG | Tenofovir/Emtricitabine/Efavirenz (Atripla) 300/200/600mg 1cp/day |
| Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia) | DRUG | Tenofovir (Viread) 300mg 1cp/day ; Lopinavir/Ritonavir (Aluvia) 400/100mg 4cp/day |
| Tenofovir/Emtricitabine (Truvada) and Zidovudine | DRUG | Tenofovir/Emtricitabine (Truvada) 245/200mg 1cp/day ; Zidovudine 300mg 2cp/day |
| Tenofovir gel | DRUG | Intravaginal (4grams)single dose followed by fourteen days |
| Tenofovir | DRUG | - |
Inclusion Criteria: * age over 18 years for Senegal and over 21 years for Cameroon * HIV-1 infected patient * patient naive from any antiretroviral treatment * CD4 cell count over 50 cells per mm3 * contraceptive method use * informed consent signed Exclusion Criteria: * opportunistic infection o...